Direct costs and survival of medicare beneficiaries with early and advanced parkinson's disease

Parkinsonism and Related Disorders

Volumn 18, Issue 4, 2012, Pages 321-326

  Kaltenboeck, A ^a   Johnson, S J ^d   Davis, M R ^a   Birnbaum, H G ^d   Carroll, C A ^b   Tarrants, M L ^b   Siderowf, A D ^c  

^a Analysis Group Inc   (United States)

^b Teva Neuroscience   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d ANALYSIS GROUP   (United States)

Author keywords

Advanced; Costs; Early; Parkinson's Disease; Survival

Indexed keywords

AGED; ALZHEIMER DISEASE; ARTICLE; BIPOLAR DISORDER; COMORBIDITY; CONTROLLED STUDY; DEMENTIA; FALLING; FEMALE; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICARE; MORTALITY; MOTOR DYSFUNCTION; NURSING HOME; PARKINSON DISEASE; PRIORITY JOURNAL; PSYCHOSIS; SURVIVAL RATE; WALKING AID; WHEELCHAIR;

AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; COHORT STUDIES; FEMALE; HEALTH CARE COSTS; HUMANS; MALE; MEDICARE; PARKINSON DISEASE; RETROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC; SURVIVAL; UNITED STATES;

EID: 84860385004     PISSN: 13538020     EISSN: 18735126     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2011.11.015     Document Type: Article

References (31)

1. Rosenthal E., Brennan L., Xie S., Hurtig H., Milber J., Weintraub D., et al. Association between cognition and function in patients with Parkinson disease with and without dementia. Mov Disord 2010 Jul 15, 25(9):1170-1176.
2. Shulman L.M. Understanding disability in Parkinson's disease. Mov Disord 2010, 1(25 Suppl.):S131-S135.
3. Schrag A., Jahanshahi M., Quinn N. How does Parkinson's disease affect quality of life? A comparison with quality of life in the general population. Mov Disord 2000 Nov, 15(6):1112-1118.
4. Siderowf A., Ravina B., Glick H.A. Preference-based quality-of-life in patients with Parkinson's disease. Neurology 2002 Jul 9, 59(1):103-108.
5. Carter J.H., Stewart B.J., Lyons K.S., Archbold P.G. Do motor and nonmotor symptoms in PD patients predict caregiver strain and depression?. Mov Disord 2008 Jul 15, 23(9):1211-1216.
6. Aarsland D., Brønnick K., Ehrt U., De Deyn P.P., Tekin S., Emre M., et al. Neuropsychiatric symptoms in patients with Parkinson's disease and dementia: frequency, profile and associated care giver stress. J Neurol Neurosurg Psychiatry 2007 Jan, 78(1):36-42.
7. Hely M.A., Morris J.G., Traficante R., Reid W.G., O'Sullivan D.J., Williamson P.M. The Sydney multicentre study of Parkinson's disease: progression and mortality at 10 years. J Neurol Neurosurg Psychiatry 1999, 67:300-307.
8. Schrag A., Jahanshahi M., Quinn N. What contributes to quality of life in patients with Parkinson's disease?. J Neurol Neurosurg Psychiatry 2000 Sep, 69(3):308-312.
9. Keranen T., Kaakkola S., Sotaniemi K., Laulumma V., Haapaniemi T., Jolma T. Economic burden and quality of life impairment increase with severity of PD. Parkinsonism Relat Disord 2003, 9:163-168.
10. Schenkman M., Zhu C.W., Cutson T.M., Whetten-Goldstein K. Longitudinal evaluation of economic and physical impact of Parkinson's disease. Parkinsonism Relat Disord 2001, 8:41-50.
11. Liou H.H., Wu C.Y., Chiu Y.H., Yen A.M., Chen R.C., Chen T.F., et al. Natural history and effectiveness of early detection of Parkinson's disease: results from two community-based programmes in Taiwan (KCIS no. 11). J Eval Clin Pract 2008 Apr, 14(2):198-202.
12. Kaiser Family Foundation. U.S. Health care costs Background Brief. Available at: [accessed 06.13.2011]. http://www.kaiseredu.org/Issue-Modules/US-Health-Care-Costs/Background-Brief.aspx.
13. Rubenstein L.M., DeLeo A., Chrischilles E.A. Economic and health-related quality of life considerations of new therapies on Parkinson's disease. Pharmacoeconomics 2001, 19:729-752.
14. Dodel R.C., Berger K., Oertel W.H. Health-related quality of life and healthcare utilization in patients with Parkinson's disease: impact of motor fluctuations and dyskinesias. Pharmacoeconomics 2001, 19:1012-1038.
15. Leibson C.L., Long K.H., Maraganore D.M., Bower J.H., Ransom J.E., O'Brien P.C., et al. Direct medical costs associated with Parkinson's disease: a population-based study. Mov Disord 2006 Nov, 21(11):1864-1871.
16. O'Brien J.A., Ward A., Michels S.L., Tzivelekis S., Brandt N.J. Economic burden associated with Parkinson disease. Drug Benefit Trends 2009, 21(6):179-190.
17. Findley L., Aujla M., Bain P.G., Baker M., Beech C., Bowman C., et al. Direct economic impact of Parkinson's disease: a research survey in the United Kingdom. Mov Disord 2003, 18:1139-1189.
18. McCrone P., Allcock L.M., Burn D.J. Predicting the cost of Parkinson's disease. Mov Disord 2007 Apr 30, 22(6):804-812.
19. Guttman M., Slaughter P.M., Theriault M.-E., DeBoer D.P., Naylor C.D. Burden of parkinsonism: a population-based study. Mov Disord 2003 Mar, 18(3):313-319.
20. Dodel R.C., Singer M., Köhne-Volland R., Szucs T., Rathay B., Scholz E., et al. The economic impact of Parkinson's disease: an Estimation based on a 3-Month Prospective analysis. Pharmacoeconomics 1998 Sep, 14(3):299-312.
21. LePen C., Wait S., Moutard-Martin F., Dujardin M., Ziegler M. Cost of illness and disease severity in a cohort of French patients with Parkinson's disease. Pharmacoeconomics 1999, 16:59-69.
22. Noyes K., Liu H., Holloway R., Dick A.W. Accuracy of Medicare claims data in identifying Parkinsonism cases: comparison with the Medicare current beneficiary survey. Mov Disord 2007 Mar 15, 22(4):509-514.
23. Deyo R.A., Cherkin D.C., Ciol M.A. Adapting a clinical Comorbidity index for use with ICD-9-CM administrative Databases. J Clin Epidemiol 1992 Jun, 45(6):613-619.
24. Bang H., Tsiatis A.S. Estimating medical costs with censored data. Biometrika 2000, 87(2):329-343.
25. Buntin M.B., Zaslavsky A.M. Too much ado about two-part models and transformation? Comparing methods of modeling Medicare expenditures. J Health Econ 2004, 23:525-542.
26. Huse D.M., Schulman K., Orsini L., Castelli-Haley J., Kennedy S., Lenhart G. Burden of illness in Parkinson's disease. Mov Disord 2005, 20:1449-1454.
27. Noyes K., Liu H., Yue L., Holloway R., Dick A.W. Economic burden associated with Parkinson's disease on elderly Medicare beneficiaries. Mov Disord 2006, 21:362-372.
28. Liou H.H., Wu C.Y., Chiu Y.H., Yen A.M., Chen R.C., Chen T.F., et al. Mortality of Parkinson's disease by Hoehn-Yahr stage from community-based and clinic series (KCIS no. 17). J Eval Clin Pract 2009 Aug, 15(4):587-591.
29. Diem-Zangerl A., Seppi K., Wenning G.K., Trinka E., Ransmayr G., Oberaigner W., et al. Mortality in Parkinson's disease: a 20-Year follow-up study. Mov Disord 2009, 24(6):819-825.
30. Guttman M., Slaughter P.M., Theriault M.E., DeBoer D.P., Math M., Naylor C.D. Parkinsonism in Ontario: increased mortality compared with controls in a large cohort study. Neurology 2001, 57(12):2278-2282.
31. Fernandez H.H., Lapane K.L. Predictors of mortality among nursing home residents with a diagnosis of Parkinson's disease. Med Sci Monit 2002 Apr, 8(4). CR241-6.